olmutinib

Uses your system voice; voice and rate in settings.

Q27088175Snapshot

≈ 4 min read

Names in other languages

  • Englisholmutinib

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

{{Infobox drug | image = Olmutinib skeletal.svg | image_class = skin-invert-image | alt = | caption = | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth | class = | ATCvet = | ATC_prefix = L01 | ATC_suffix = EB06 | legal_AU = | legal_AU_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status = Approved in South Korea | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 1353550-13-6 | PubChem = 54758501 | DrugBank = | ChemSpiderID = 45743494 | UNII = CHL9B67L95 | KEGG = D10859 | ChEBI = | ChEMBL = | synonyms = HM-61713, BI-1482694 | IUPAC_name = N- {3-[(2- {[4-(4-Methyl-1-piperazinyl)phenyl]amino}thieno[3,2-d]pyrimidin-4-yl)oxy]phenyl}acrylamide | C=26 | H=26 | N=6 | O=2 | S=1 | smiles = CN1CCN(CC1)c2ccc(cc2)Nc3nc4ccsc4c(n3)Oc5cccc(c5)NC(=O)C=C | StdInChI=1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30) | StdInChIKey = FDMQDKQUTRLUBU-UHFFFAOYSA-N }} Olmutinib (INN) is an investigational anti-cancer drug.…

{{Infobox drug | image = Olmutinib skeletal.svg | image_class = skin-invert-image | alt = | caption = | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth | class = | ATCvet = | ATC_prefix = L01 | ATC_suffix = EB06 | legal_AU = | legal_AU_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status = Approved in South Korea | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 1353550-13-6 | PubChem = 54758501 | DrugBank = | ChemSpiderID = 45743494 | UNII = CHL9B67L95 | KEGG = D10859 | ChEBI = | ChEMBL = | synonyms = HM-61713, BI-1482694 | IUPAC_name = N- {3-[(2- {[4-(4-Methyl-1-piperazinyl)phenyl]amino}thieno[3,2-d]pyrimidin-4-yl)oxy]phenyl}acrylamide | C=26 | H=26 | N=6 | O=2 | S=1 | smiles = CN1CCN(CC1)c2ccc(cc2)Nc3nc4ccsc4c(n3)Oc5cccc(c5)NC(=O)C=C | StdInChI=1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30) | StdInChIKey = FDMQDKQUTRLUBU-UHFFFAOYSA-N }} Olmutinib (INN) is an investigational anti-cancer drug.

It acts by covalently bonding to a cysteine residue near the kinase domain of epidermal growth factor receptor (EGFR). In the US, it was given a breakthrough therapy designation in non-small cell lung cancer (NSCLC) in December 2015, and In South Korea, the drug was approved in May 2016 for the second-line treatment of NSCLC with the T790M mutation of EGFR. Resistance to olmutinib has been reported; a person's cancer started progressing after they developed a C797S mutation in EGFR.

Olmutinib was discovered by Hanmi Pharmaceutical and licensed to Boehringer Ingelheim in 2015 in an agreement with a $50 million up front payment and up $680 million in milestones. In November 2015 Hanmi granted an exclusive license to sell olmutinib in China to the Chinese company ZAI Labs.

Evidence and sources

On September 30, 2016, Korean regulatory authorities issued a safety alert about olmutinib in which it described two cases of toxic epidermal necrolysis, one of which was fatal, and a case of Stevens–Johnson syndrome; Boeheringer announced the termination its deal with Hanmi the same day, citing that the decision came after a review of "all available clinical data" on the drug, and also referring to competing drugs.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1332195655 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.